Dakota Wealth Management Buys 39,724 Shares of Tempus AI, Inc. (NASDAQ:TEM)

Dakota Wealth Management boosted its holdings in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 189.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 60,668 shares of the company's stock after buying an additional 39,724 shares during the period. Dakota Wealth Management's holdings in Tempus AI were worth $2,048,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. First Horizon Advisors Inc. purchased a new position in Tempus AI during the third quarter valued at $30,000. FNY Investment Advisers LLC bought a new stake in shares of Tempus AI in the fourth quarter worth about $67,000. Vestor Capital LLC purchased a new stake in shares of Tempus AI in the third quarter worth about $153,000. Stifel Financial Corp bought a new position in Tempus AI during the third quarter valued at approximately $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Tempus AI during the third quarter valued at approximately $258,000. 24.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TEM has been the topic of several recent research reports. Wolfe Research started coverage on Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Bank of America upped their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and lifted their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler restated a "neutral" rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Tempus AI currently has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Insider Activity

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the company's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at $358,780,403.82. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862,758 shares of company stock valued at $79,585,675.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded down $3.44 during mid-day trading on Friday, reaching $51.40. The company had a trading volume of 12,994,864 shares, compared to its average volume of 9,294,415. The business's 50-day moving average is $44.36 and its 200-day moving average is $47.59. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.